tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

SomnoMed Reports 21.6% Revenue Growth in 2025 Despite Losses

Story Highlights
  • SomnoMed Limited reported a 21.6% revenue increase to $111.5 million in 2025.
  • The company showed a 71.8% improvement in post-tax losses but will not pay a dividend for 2025.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
SomnoMed Reports 21.6% Revenue Growth in 2025 Despite Losses

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Somnomed Limited ( (AU:SOM) ) just unveiled an announcement.

SomnoMed Limited has released its 2025 Full Year Report, highlighting a significant 21.6% increase in revenue from ordinary activities to $111.5 million. Despite reporting a loss from ordinary activities after tax of $3.5 million, this marks a substantial improvement of 71.8% compared to the previous year. The company announced that no dividend will be paid for the year ended 30 June 2025, reflecting a strategic focus on reinvestment and growth. The results suggest a positive trajectory in financial performance, potentially enhancing SomnoMed’s positioning in the sleep-related breathing disorder treatment industry.

The most recent analyst rating on (AU:SOM) stock is a Buy with a A$1.00 price target. To see the full list of analyst forecasts on Somnomed Limited stock, see the AU:SOM Stock Forecast page.

More about Somnomed Limited

SomnoMed Limited is a public company specializing in treatment solutions for sleep-related breathing disorders such as obstructive sleep apnea, snoring, and bruxism. The company has commercialized its products based on extensive clinical research, supporting independent clinical research, continuous innovation, and medical manufacturing standards. Its flagship product, SomnoDent, is a state-of-the-art and clinically proven medical oral appliance therapy used by over 1 million patients in more than 20 countries.

Average Trading Volume: 65,479

Technical Sentiment Signal: Hold

Current Market Cap: A$159.3M

Find detailed analytics on SOM stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1